The latest price target for Aura Biosciences (NASDAQ:AURA) was reported by JMP Securities on September 13, 2024. The analyst firm set a price target for $23.00 expecting AURA to rise to within 12 months (a possible 130.69% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Aura Biosciences (NASDAQ:AURA) was provided by JMP Securities, and Aura Biosciences maintained their market outperform rating.

There is no last upgrade for Aura Biosciences

There is no last downgrade for Aura Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aura Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aura Biosciences was filed on September 13, 2024 so you should expect the next rating to be made available sometime around September 13, 2025.

While ratings are subjective and will change, the latest Aura Biosciences (AURA) rating was a maintained with a price target of $19.00 to $23.00. The current price Aura Biosciences (AURA) is trading at is $9.97, which is out of the analyst’s predicted range.